first_imgCoronavirus | Juneau | Local GovernmentHundreds of appointments still available for Juneau’s next mass vaccination clinicMarch 2, 2021 by Jeremy Hsieh, KTOO Share:Update | 6:18 p.m.COVID-19 vaccination stations and a waiting area during Juneau’s first mass vaccination event on Jan. 17, 2021, at Centennial Hall. The city estimates more than 1,100 people were vaccinated that weekend. (Photo by Rashah McChesney/KTOO)As of Tuesday afternoon, nearly 500 appointments were still available for Juneau’s next mass vaccination clinic.Emergency planning chief Robert Barr said the remaining appointments are for Saturday, March 13.“We’re pretty confident that they will fill up … but we do need help in getting the word out,” he said.Eligible residents can sign up online or by calling the city’s COVID hotline at 586-6000. Otherwise ineligible residents can also get a spot by helping a senior get vaccinated.Vaccines may also be available through other channels, including area pharmacies and doctor’s offices. Members of the military may be eligible through the U.S. Department of Defense and veterans through Veterans Affairs.In Juneau, the Southeast Alaska Regional Health Consortium is making the vaccine available to all of its beneficiaries and existing patients. To be considered for future appointments, sign up at covid19.searhc.org.So far, Juneau city officials think 30% of Juneau’s 16 and older population have gotten at least one dose of the vaccine.Barr and other local officials spoke during the city’s weekly COVID-19 community update on Tuesday.Deputy City Manager Mila Cosgrove said that last month, Juneau averaged 3.08 new COVID cases per day. That’s about one third of the high in November, 9.37.“Definitely moving in the right direction,” Cosgrove said.She said one question she is getting a lot is, how will we know when we’re out of this?“We are thinking about that, we are looking at it. We don’t have defined answers yet, but that is very much in our minds as we look at the upcoming months to try to navigate that terrain,” she said.City officials are still worried about other factors that could upend the trend lines.“The thing I think that keeps us all awake a little bit at night is knowing that some of the more aggressive variants of COVID are here in Alaska,” Cosgrove said. “We have not yet identified any in Juneau, but it is likely going to happen.”Cosgrove said any positive case identified among airport travelers is sent to a state lab to quickly identify potential variants.Original story | 3:40 p.m.Juneau city officials are holding their weekly COVID-19 community update at 4 p.m. today over video conference. You can watch on this post, through the City and Borough of Juneau’s Facebook page or on Zoom.Members of the city’s emergency operations center will provide information about the local COVID-19 response and answer questions. Community members can email questions in advance.The city’s next mass vaccination clinic is scheduled for March 12 and 13. As of Monday, 746 appointments were available. Eligible residents can sign up online or by calling the city’s COVID hotline at 586-6000.Vaccines may also be available through other channels, including area pharmacies and doctor’s offices. Members of the military may be eligible through the U.S. Department of Defense and veterans through Veterans Affairs.In Juneau, the Southeast Alaska Regional Health Consortium is making the vaccine available to all of its beneficiaries and existing patients. To be considered for future appointments, sign up online.So far, Juneau city officials think 30% of Juneau’s 16 and older population have gotten at least one dose of the vaccine.As of Tuesday afternoon, city officials know of 18 residents with active cases of COVID-19. The figure includes Juneau residents in Juneau, Juneau residents outside of Juneau, and Alaska residents in Juneau, like legislators and their staff.Share this story:last_img read more

first_img The trial is expected to start soon, likely in November, Farrar said — with Congo’s National Institute of Biomedical Research serving as the sponsor for the trial.But there remain details to be worked out. An ethics committee advising the Congolese government is still reviewing the protocol.The protocol is written in such a way as to allow countries a little flexibility. While DRC has indicated it will run four arms — meaning all patients will be randomized to receive one of the drugs — other countries will have the option to add a control arm that would allow the drugs to be compared to standard care.Antierens said there’s a problem with that idea. There is no one standard of care for Ebola, she said, and none of the interventions used in the treatment of Ebola patients has been proved to actually improve survival. That’s not to say they don’t help, only that there have never been clinical trials to show they do.In the case of the Ebola therapeutics, if there is no control arm, how do you compare four different therapies? One idea has been to use ZMapp — which was studied in the West African outbreak — as an “anchor arm,” comparing the other drugs to it.The ZMapp trial appeared to generate a signal that patients who were infused with the antibody cocktail were more likely to survive, but the trial was started late in the outbreak and did not manage to enroll enough patients to come to a conclusive answer. Not everyone is on board with the notion of using ZMapp as an anchor arm, Antierens said. “We need to start randomizing. We need to start generating evidence and having a harmonized way of collecting data,” said Dr. Annick Antierens, MSF’s medical department strategic adviser, who has been involved in the negotiations.There have been some data gathered from the cases treated to date, but without any kind of standardization, it’s not clear how much can be deduced from it. Antierens likened it to comparing “apples with cherries and leeks and melons.”Dr. Mike Ryan, deputy head of the WHO’s emergency response operation, insisted this period of compassionate use has allowed the Ebola treatment centers to get to the point where they are functioning well, and has given their staff time to become familiar with how to administer the drugs. ZMapp is difficult to use; it takes three infusions, given over hours. If patients are treated with Remdesivir, their liver function must be analyzed regularly.“Both NGOs and the Congolese doctors and nurses have had this clinical experience over the weeks,” said Ryan, who spent the last month in the outbreak zone. “It’s a mechanical process and it requires a skill. And you get that muscle memory from doing that and you become more and more comfortable.”“You don’t just push the ‘RCT button’ in a context like this, you know?” he added, using an acronym for randomized controlled trials. By Helen Branswell Nov. 12, 2018 Reprints Health officials are preparing to launch a clinical trial designed to test whether experimental Ebola therapies improve patients’ chances of survival in the outbreak in the Democratic Republic of the Congo — a landmark moment in the world’s efforts to respond to this and future crises.The randomized controlled trial will compare three different antibody treatments and an antiviral drug to each other, rather than involving a placebo. It is unlikely that the trial will produce clear results based on a single epidemic; it is expected to span several outbreaks and countries — a novel and challenging design.In the current outbreak, the trial will be made all the more complicated by a difficult security environment.advertisement Ebola outbreak in DRC sets up another test for experimental treatments Please enter a valid email address. A health worker gets ready to perform medical checks inside an Ebola treatment center in the Democratic Republic of the Congo. JOHN WESSELS/AFP/Getty Images Newsletters Sign up for Morning Rounds Your daily dose of news in health and medicine. Related: Leave this field empty if you’re human: Another possibility, said Dr. Marie-Pierre Preziosi, is to compare the three monoclonal antibody treatments to each other, and to compare the monoclonals to the antiviral. Preziosi is one of the leads of a WHO program designed to spur development of medical countermeasures for disease threats that don’t attract commercial pharmaceutical manufacturers.A data safety monitoring board will review results at preset intervals. If any of the drugs don’t appear to be working — or conversely appear to be much more effective than the others — the board will advise the trial team on whether to drop a drug or discontinue the trial, Preziosi said.Given the difficulty of conducting clinical trials during an Ebola outbreak — let alone an Ebola outbreak in such a highly volatile setting — this needs to be done right, Ryan said.“I do think we need a period of solid operational and logistics planning in the field to make this a success. Everyone wants this to be a success,” he added. “Everyone wants a good RCT to finally work out what value each of these therapies has in the treatment of of Ebola. We’ve seen promising signs … but no one will ever know until we do a proper RCT.” At a dangerous point in the Ebola outbreak, residents increase cooperation with containment efforts Helen Branswell HealthA pivotal day in world’s response to Ebola nears: the launch of a clinical trial Tags infectious diseasepublic health STAT+: Privacy Policy Related: The four experimental therapies that will be tested have been used for weeks in Ebola treatment units being operated by nongovernmental organizations Doctors Without Borders (MSF) and Alima. Those therapeutics are the Gilead antiviral drug Remdesivir and three monoclonal antibody preparations: ZMapp, made by Mapp Biopharmaceuticals, Regeneron’s REGN 3470-3471-3479, and mAb 114, which is being developed by the National Institutes of Health and DRC’s National Institute of Biomedical Research.As of Friday, 139 patients had received one of the four.To date, there have been 329 confirmed and probable cases of Ebola and 205 deaths, making this Ebola outbreak, which began in July, the third largest on record.It is unusual for unlicensed drugs to be used in such quantities outside of the context of a clinical trial. In this case, the authorization came through a sort of compassionate use protocol established by the WHO.The idea was that the protocol would serve as a bridge to allow use while a clinical trial was being designed and signed off on by the numerous parties that have a stake in the process. But that process has taken longer than many people anticipated, and there has been frustration and concern about continued use of experimental drugs that have been shown to increase survival in animal studies, but may or may not work as well in people. “I don’t think the world quite appreciates the challenge of the environment in which this is happening,” said Dr. Jeremy Farrar, head of the Wellcome Trust and co-chair of a group that has been working under the auspices of the World Health Organization to draft the trial protocol.“People are being shot at, and it’s not just the occasional bit of gunfire,” Farrar said of the security environment in North Kivu. “There’s mortars, there’s kidnappings — it is an intensely fragile environment with a lot of conflict that’s been going on for years.”advertisement @HelenBranswell Senior Writer, Infectious Disease Helen covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Exclusive analysis of biopharma, health policy, and the life sciences. About the Author Reprintslast_img read more

first_img Enter the FDA. Its 44-page proposal, published formally in late December, is serious and well thought through. To ensure the safety of the U.S. drug supply, FDA has set out a detailed, complex, step-by-step process that a state would need to follow if it wishes to import drugs for its Medicaid and other state programs, or for use by private health plans.advertisement About the Author Reprints Adobe For decades, critics of the U.S. drug pricing system have advocated importing drugs from Canada as a convenient shortcut to lower prices. The Food and Drug Administration’s recent release of a proposed regulation to create a process for approving state-sponsored importation plans is one step closer to that goal. A closer look shows that it’s actually a false step.Career FDA staff, supported by previous FDA commissioners and Health and Human Services secretaries, have long maintained that there is no way to open a drug import channel into the U.S. pharmaceutical supply chain without violating the 2003 law authorizing Canadian drug imports that required the FDA to certify that importation would create no safety risk to the public. Now, with a heavy twist of the arm from President Trump’s strong support for importation, the FDA has been forced to describe a possible pathway for it.Importation has never been about actually bringing drugs into the U.S. — it’s about bringing their prices here. The drugs that people want to import are not like Caspian Sea caviar, French Bordeaux, or Chilean sea bass. The drugs Americans want are already available in the U.S. in plentiful quantities, and some are even produced or finished in U.S. factories. But the U.S. wholesale price of these drugs is often multiples of what drug companies charge purchasers outside the U.S. Inconveniently, we can only import the prices along with the actual drugs.advertisement Bills in the House of Representatives (H.R. 3) and the Senate (S. 2543) that take direct aim at high drug prices make drug importation from Canada seem like a bit of an anachronism. However, it is an anachronism that enjoys widespread support as a quick fix since these bills are far from certain to advance in the near future. Florida has already advanced a detailed drug import plan, and several other states have taken steps toward devising their own plans. With Florida a likely battleground state in 2020, the president is eager to deliver its voters lower drug prices. Related: Trump administration unveils plan to allow drug importation from Canada Please enter a valid email address. To do its best to ensure safety, the FDA proposes allowing only the shortest possible supply chain: manufacturer to exporter to importer to patient. While that makes sense, it also creates a practical problem for the program’s success: Why would a manufacturer sell its drug to anyone who is going to ship it into the U.S. and undercut its prices here?In other countries with active drug sales across country borders, such as those in the European Union, exporters can buy their drugs from other wholesalers, and even pharmacies, through a process of drug arbitrage in which they find products in low price markets and resell them in high price markets. That would not be allowed if the FDA regulation becomes final.And then there is the issue of why Canada would participate in this scheme when exports from the country’s small market could create supply shortages that would harm Canadians. Health Canada has already signaled it would “take action to ensure Canadians have uninterrupted access to the prescription drugs they need.” The FDA proposal has given the Canadians an easy path to such action. To serve as a drug exporter, a Canadian entity must have — you guessed it — a license from Health Canada. How quickly would Canada impose a new licensing requirement that prohibits participation in the U.S. import program? Leave this field empty if you’re human: Even assuming that a Canadian exporter can get its hands on enough product to export, and that the Canadian government decides to look the other way in the interest of promoting its own businesses or not angering the Trump administration, the proposed rule raises the very real question of whether the costs of complying with its many requirements are worth the savings.Here are just a few of the duties an importer would have to agree to:screening the drugs for damage and counterfeitingrelabeling the drug with the U.S.-approved label informationgaining FDA approval for each shipmenthaving samples of each shipment tested at an FDA approved laboratorycreating a system for collecting and investigating any physician or consumer reports of adverse reactionssharing with the FDA detailed records that each requirement has been metEach of these is costly, and a misstep could lead the FDA to terminate an importer’s ability to do business. Like a regulatory game of Jenga, the FDA has also stipulated that if the courts remove any piece of its process, the entire thing tumbles down and the FDA will terminate this entire importation plan.And yet the FDA is saying, “If you really want to try, go for it!” Whether anyone takes the agency up on the offer will depend on what the final rules look like. I anticipate that importation proponents will raise objections to some of the requirements in comments that are due by March 9. Based on typical regulatory timetables, the FDA could finalize its rule and be open to considering state applications as early as this summer.Given the political momentum behind importation, it’s a safe bet that one or more states will take up the challenge and at least initiate the process of gaining FDA approval for its importation plans and start the process of seeking a U.S.-based drug wholesaler or pharmacy partner. But given the approach FDA is proposing, it’s a long shot that states will see significant savings, or even enough to justify the cost of setting up such a program.If drug importation is not the answer to high drug pricing, it will continue to fall to Congress and the White House to see if agreement is possible on any of the current proposals for the U.S. to directly deal with prices rather than delegating that role to our neighbors to the north.Ian D. Spatz is a senior adviser with Manatt Health.center_img By Ian D. Spatz Feb. 18, 2020 Reprints @rockcreekpolicy First OpinionFDA calls states’ bluffs on drug importation Privacy Policy Newsletters Sign up for D.C. Diagnosis An insider’s guide to the politics and policies of health care. Ian D. Spatz [email protected] Tags drug pricingpharmaceuticalslast_img read more

first_img“Apparently, the corporate credit market does not yet expect the latest bout of trade frictions to prompt a widespread contraction of core profits capable of significantly worsening the default outlook,” the report said.The high-yield bond market was much calmer during last year’s bouts of market volatility in February and December, Moody’s said, making it a better predictor than the VIX of financial market performance for the three months that followed.Yields on the 10-year U.S. Treasury, the 10-year Canadian government bond and the German 10-year government bond have all declined this week. Keywords Bond,  Fixed-income investments With bond yields low and rising, what is the price of safety? Share this article and your comments with peers on social media Related news usiness investment opportunities on a global scale kentoh/123RF IE Staff When bond ratings slip, investors shrug As equities wobbled this week amid intensified U.S.-China trade conflict, “the corporate credit market was relatively calm,” says a report from Moody’s Analytics published Thursday.Compared to the CBOE Volatility Index’s (VIX) dramatic jump earlier this week, the widening of the high-yield bond spread was moderate, the report said, as was the spread of JPMorgan’s emerging market country bond index. Catastrophe bond market gains momentum Facebook LinkedIn Twitterlast_img read more

first_img Facebook LinkedIn Twitter Related news “This research project is critically important to understanding and responding to the challenges these businesses face every day,” said Pat Chaukos, deputy director of OSC LaunchPad, in a statement.As part of its dual efforts to enhance innovation and reduce the regulatory burden, the OSC has pledged to provide more regulatory flexibility to innovative businesses.“We are inviting these businesses to work with us to identify and help modify regulatory requirements that do not properly take account of their business models,” the regulator said in the burden reduction report it released last year.The anonymous survey closes on Jan. 10. Keywords Innovation,  FintechCompanies Ontario Securities Commission hand drawing creative business strategy with light bulb as concept everythingpossible/123RF Regulators must avert looming irrelevance: IAP FSB seeks faster, cheaper global payments Share this article and your comments with peers on social media The Ontario Securities Commission (OSC) is calling on innovative businesses to provide feedback on regulatory barriers and other challenges to raising capital.The OSC’s fintech unit, OSC LaunchPad, has a survey to collect input that, it says, will provide the regulator with insight on how it can better support innovation. ESMA launches digital finance consultation James Langton last_img read more

first_imgHome Industry News Releases Saxco International, LLC Helps Luxco Turn a Second Limited Edition Ducks Unlimited…Industry News ReleasesSpirits BusinessSaxco International, LLC Helps Luxco Turn a Second Limited Edition Ducks Unlimited Decanter for Lord Calvert Canadian Whiskey into RealityBy Press Release – September 12, 2017 77 0 Share Previous articleDelicato Family Vineyards Adds Clarice Turner to Advisory Board of DirectorsNext articleNew Winery, Wapisa, Launches in Patagonia, Argentina Press Release AdvertisementLord Calvert® Canadian Whisky, which had previously established a partnership with Ducks Unlimited, the world’s leader in wetlands and waterfowl conservation, announced that as part of its continuing partnership it is releasing a second 750ml custom decanter which will be available beginning in September  throughout the United States. The partnership showcases the strong Canadian heritage of both Lord Calvert Canadian Whisky and Ducks Unlimited, as well as their passion for the outdoors.Saxco International, LLC, of Horsham, PA world-wide packaging specialists for the wine, spirits, beer and food industries with a vast global resource network was selected again to help turn the all-important packaging concept into reality. It had assisted with the packaging for the first custom decanter which was released in 2016. According to Jason Craig, regional sales representative for Saxco International, “Saxco was able to provide Luxco with a turnkey solution that leveraged its extensive supply chain and creative design process to conceptualize, develop and produce the decanter on time and on budget.”“Saxco’s packaging design team worked closely with Luxco’s new product development and marketing teams to design the custom hand-painted ceramic decanter of a Yellow Labrador retrieving a duck that is packaged in a beautiful gift box,” states Craig. “The total solution included a variety of different packaging types. The ceramic decanter with a bar top closure was made at a reliable quality overseas supplier. The full color corrugated gift box with a protective thermoform insert and printed corrugated shipping box that the decanter was then packed in was manufactured by two long-time Saxco resource partners located in Indiana and Pennsylvania.”“Each 750ml decanter is hand painted, hand labeled and hand filled with smooth and flavorful Lord Calvert Canadian Whisky,” says Jim Walden, Saxco packaging & printing specialist who also worked on the project with Jason Craig. “Saxco worked tirelessly to make sure the gift box and shipper package would not only protect the decanter, but would provide an amazing user experience with a terrific overall appearance,” notes Walden.   “We are excited to partner with Ducks Unlimited and we support their mission to conserve and restore America’s wetlands,” says Fletcher Buchman, brand manager at Luxco. “We are pleased to be donating a portion of the proceeds from our second limited edition decanters to this organization.”Lord Calvert Canadian Whisky is distilled in the heart of Canada, offering a smooth flavor with a touch of sweetness from a mixture of rye, corn, wheat and barley mash aged for 36 months. The brand which is 80 proof and 40-percent alcohol by volume, celebrated its 50th anniversary in 2016. The suggested retail price for the 750ml decanter and gift box is $99.99 For additional information, visit the web at www.lordcalvertwhisky.com. Also, the decanter and gift box will be available on line without whisky for $65.About LuxcoLuxco, Inc. is a leading producer, supplier, importer and bottler of beverage alcohol products. Luxco’s mission is to meet the needs and exceed the expectations of consumers, associates and business partners. Founded in St. Louis in 1958, Luxco remains locally owned and operated by the Lux family. Currently, Luxco is constructing its first bourbon distillery-Lux Row Distillers-bringing the Lux family’s legacy to the heart of Bourbon Country in Bardstown, Kentucky. Lux Row Distillers will be home to many of the company’s bourbon brands, such as Rebel Yell, Blood Oath, David Nicholson and Ezra Brooks. Luxco also has built a new distillery in the highlands of Jalisco, Mexico-Destilation Gonzalez Luxco-where the company’s 100 percent agave tequilas, El Mayor and Exotico, will be produced. Luco’s innovative and high-quality brand portfolio also includes Everclear Grain Alcohol, Pearl Vodka, Saint Brendan’s Irish Cream, and other well-recognized brands. For more information about the company and its brands, visit www.luxco.com. About Saxco International, LLCSaxco International, LLC, “Your clear choice for premium packaging solutions,” has more than 30 years of industry experience, providing a broad range of packaging products and services to the liquor, wine, beer and food industries. The company’s products and services include expert consultation from design to development, as well as customized services for packing. Saxco is headquartered in suburban Philadelphia, Pennsylvania with offices and warehouses in Louisville, Kentucky, Concord and Napa, California, Portland, Oregon, Tampa, Florida, Toronto, Ontario, Cincinnati, Ohio, Mountainside, New Jersey, Statesville, North Carolina, Carlisle, Pennsylvania, Grand Rapids, Michigan, Denver, Colorado and Qingdao, China. For additional information call 215-443-8100, fax 215-443-8370 or on the web at www.saxco.com.Advertisement Pinterest Twitter ReddIt Email TAGSConsumerLord Calvert Canadian WhiskeyLuxcoSaxco International Linkedin Facebooklast_img read more

first_imgHome Industry News Releases Three Sticks Wines’ Ryan Prichard Named Winemaker of the YearIndustry News ReleasesWine BusinessThree Sticks Wines’ Ryan Prichard Named Winemaker of the YearBy Press Release – September 1, 2020 733 0 TAGSfeaturedpeopleRyan PrichardThree Sticks Wines Advertisement2020 Rising Wine Star Awards recognize the new generation of outstanding wine industry achievers presented by LuxeSF and Modern LuxurySonoma, CA (September 1, 2020) — Three Sticks Wines is proud to announce that winemaker Ryan Prichard has been chosen as the 2020 Rising Wine Star Winemaker of the Year from LuxeSF and Modern Luxury, publishers of San Francisco and Silicon Valley magazines. For the fourth year, LuxeSF is presenting the Rising Wine Star Awards to acknowledge individuals and organizations that are building reputations and conquering an ever-changing marketplace, and who epitomize the new generation of the wine industry in California, specifically Napa and Sonoma.Previous awards have been presented to Benoit Touquette (Realm Cellars, Hartwell, Kata, Fait-Main), Julien Fayard (Le Pich, Purlieu, Somnium, Azur, Covert Estate, Empreinte), and Nigel Kinsman (Accendo Cellars, Wheeler Farms Winery, Bella Oaks, Kinsman Wine).“I am very humbled and honored to receive this award from LuxeSF and Modern Luxury,” said Prichard. “From our vineyard team that grows us the highest quality grapes and our production team that crafts the wine daily, to our exceptional hospitality team and those working together to bring these wines to our customers, we succeed together, and I couldn’t be more proud.”“We are thrilled that Ryan is being recognized as a leader in the industry and for the programs and portfolio of incredible wines he has created while Winemaker at Three Sticks,” said Prema Behan and Bill Price, Co-Founders of Three Sticks Wines. “This award is an exciting achievement for Ryan and the team. They work to craft the best expressions of the Price Family Estate vineyards and it shows.”Ryan Prichard has been committed to crafting excellence while elevating the region utilizing the unique and diverse terroir coupled with innovation and skill. He grew up in northern California and began making wine in Sonoma County in 2008. Ryan has worked alongside many esteemed winemakers in various Sonoma County wineries including Williams Selyem, Copain Custom Crush, Medlock Ames and Graft Wines, and is concurrently the Winemaker at Flambeaux Wine in Dry Creek Valley.Ryan joined Three Sticks Wines as Winemaker in 2015 alongside Director of Winemaking, Bob Cabral. His focus is crafting pinot noir and chardonnay that showcases Three Sticks’ exceptional estate vineyard sites, producing wines of distinction and acclaim. Ryan conceptualizes winemaking as an endeavor in balancing contrasts, “you must be precise yet flexible; organic yet by design; create for immediate gratification yet stand the test of time.” As we forge ahead in a new and different economic and societal landscape, Ryan hopes wine can play a small part in bringing comfort, understanding, and connections to people in our communities.Because of continuing SIP conditions, the 2020 Rising Wine Stars awards will be formally presented via a special Zoom awards ceremony in the presence of 300+ wine industry marketing, sales and hospitality influencers, representing Napa and Sonoma wineries and wine-related organizations. Date to be announced soon.The 2020 Rising Wine Stars Awards acknowledge outstanding Napa and Sonoma wine industry achievers and achievements in the following categories:Winery of the YearWinemaker of the YearMarketer of the YearThe Community Service AwardThe Hospitality & Guest Relations AwardThe Innovation AwardThe selection process is agnostic with respect to age, length of service and size of winery or organization represented. The awardees are chosen based on their current reputation and level of success, but more so for the potential that they exhibit as future industry leaders and innovators. A 13-person panel of respected industry professionals made the final selections from multiple candidates across all six award categories.Three Sticks WinesThree Sticks Wines is a boutique, family-owned winery led by winemakers Bob Cabral and Ryan Prichard, along with proprietor and vineyard owner Bill Price. Three Sticks is characterized by commitment to site specific wines, stewardship of land, people, and history, with a down-to-earth approach to business and life. They craft small-lot, artisanal wines from six Grand cru level Estate vineyards in Sonoma County, including Durell Vineyard, Gap’s Crown Vineyard, and Walala Vineyard. Founded in 2002, the winery is named for owner William S. Price III’s surfing nickname, “Billy Three Sticks,” assigned to him in his youth as a reference to the three Roman numerals that follow his name.The Vallejo-Casteñada Adobe (built in 1842 and current home to the hospitality of Three Sticks Wines), was constructed by Captain Salvador Vallejo, brother of General Mariano Guadalupe Vallejo, the Comandante Générale of the northern territory of Mexico (modern day Sonoma). Bill and Eva Price purchased the property in 2012 and embarked on a two year preservation project. The Three Sticks team worked closely with Sonoma historians and the Sonoma League for Historic Preservation to restore and protect the historic fabric of the property.www.threestickswines.comAdvertisement Share Facebook Pinterest Email Twitter Linkedin ReddIt Previous articleFormer NFL Championship and Hall of Fame Coach Dick Vermeil to Host Virtual Wine Tasting Event With Former NFL Players Devon Still and Rich Mauti on September 30Next articleRodney Strong Wine Estates Launches New Brand, Knotty Vines Press Releaselast_img read more

first_imgFacebookTwitterWhatsAppEmail Minister of Finance, Planning and the Public Service, Hon. Dr. Peter Phillips, has underscored the Government’s commitment to urgently address the unwieldy public sector bureaucracy, and is prepared to include performance benchmarks in future agreements with the International Monetary Fund (IMF). He was addressing the Jamaica Stock Exchange’s (JSE) 7th Regional Investments and Capital Markets Conference on January 25, at the Jamaica Pegasus Hotel in New Kingston. In the effort to further fast-track project implementation, the Minister explained that  “to get those projects that are being planned into the ground as quickly as we can, we are going to establish, under the leadership of the Prime Minister through the (National) Development Council, mechanisms to pull the roadblocks out the way as quickly as possible.” Bureaucracy has been cited as a major and longstanding constraint to the conduct of profitable business in Jamaica. The Minister identified the high cost of energy and the “cumbersomeness” of the bureaucracy as major impediments to investments, economic growth and sustainable development. He gave the Government’s undertaking to create a business-friendly environment, including a “general effort to reduce the cumbersomeness of the bureaucracy that too many have to encounter in dealing with simple things like transferring property and getting building and development approvals.” The Finance Minister noted that the process of easing the inordinate delays “is going to be a central feature of the effort of a number (of ministries and) ministers, particularly the Minister of Justice, who has very direct experience of the way in which business activities are stymied and impeded by the cumbersome bureaucracy.” He explained that the overall intention is to establish benchmarks adding that the Government is “prepared to include these benchmarks in any Fund agreement going forward to reduce the scale and level of this bureaucracy and  create a more friendly and facilitatory business environment, because we need to have the engine of the private sector revving at full speed.” Advertisements RelatedCumbersome Bureaucracy to be tackled RelatedCumbersome Bureaucracy to be tackled By Allan Brooks, JIS Senior Reporter RelatedCumbersome Bureaucracy to be tackled Cumbersome Bureaucracy to be tackled Finance & Public ServiceJanuary 26, 2012last_img read more

first_img Today is the 30th anniversary of Eddie Fullerton’s murder Pinterest Homepage BannerNews WhatsApp RELATED ARTICLESMORE FROM AUTHOR Google+ Consultation launched on proposal to limit HGV traffic in Clady Donegal hoteliers enjoy morale boost as bookings increase Facebook Hospitalisations rise as Donnelly suggests masks will stay ’til autumn Twitter A Donegal Deputy has said the Government may finally be facing up to the seriousness of Brexit and its impact for border regions.The uncertainty of the border regions following Britain’s decision to leave the EU has been much debated, Deputy Charlie McConalogue says it now appears the Government has ‘finally woken up’.New Taoiseach Leo Varadkar announced this week as part of his cabinet selection that special responsibility for Brexit has been assigned to Foreign Affairs Minister, Simon Coveney.Donegal Deputy Charlie McConalogue has welcomed this move, he says it is a step in the right direction but still does not go far enough.Deputy McConalogue is calling on Leo Varadkar to appoint a specific Minister on Brexit.Speaking in relation particularly to border regions, he says there is a real fear of a hard border, something that will impact all communities and sectors including agriculture, tourism and local businesses.center_img Pinterest By News Highland – June 18, 2017 Previous articleDerry Minors reach third successive Ulster FinalNext articleStage 19 of the Joule Donegal International Rally – Update News Highland Google+ Facebook Disruption to cancer service will increase mortality – Oncologist Twitter Government finally facing up to seriousness of Brexit – Deputy McConalogue 45 new social homes to be built in Dungloe WhatsApplast_img read more

first_img Shippers, forwarders, shipping lines and container terminals “urgently” need to begin discussions over the practicalities of implementing the International Maritime Organization’s (IMO) new regulation on container weights.That was one of the chief conclusions of Friday’s International Cargo Handling Coordination Association (ICHCA) seminar on container weighing in London, with some delegates warning that the legislation, due on 1 July 2016, could lead to chaos.The new requirements, formally an amendment to the IMO’s existing Safety of Life at Sea (Solas) regulations, have been designed to reduce the number of accidents globally caused by containers whose weights have been misdeclared by shippers and their agents.The new law says they must verify the weight declared on the bill of lading. It has been criticised as difficult to enforce, while many sea freight buyers are said to be completely unaware of the legislation. By Gavin van Marle 15/09/2015 From next summer, shippers will have to prove the weight of their containers through one of two methods: weighing the loaded container (Method 1); or weighing the cargo and adding the tare weight of the container (Method 2).Richard Brough, ICHCA technical advisor, said: “There is no exemption from weighing in some form – if you are a Method 2 shipper, you will still have to weigh the cargo, the calculation aspect comes from adding the cargo weight with the tare weight of the container.”Washington-based liner shipping lobby group the World Shipping Council (WSC) was one of the proponents of the new legislation. It initially insisted on Method 1, but later acquiesced to shipper arguments, led by the Global Shippers Forum, that Method 2 would provide the same level of assurance to ships’ masters, ultimately be responsible for accepting or rejecting containers waiting to be loaded.However, it will remain up to national jurisdictions to decide if they will accept both methods, and WSC senior vice president Lars Kjaer asked what will happen in jurisdictions that have decided to only accept Method 1 as proof of the verified gross mass (VGM) of a container.“But, come 1 July next year, there will be containers showing up at the gate without signed verification forms – so how do we manage that? What do we do with those boxes? The whole operational side needs to be discussed and sorted out,” he said.In contrast, the UK’s enforcement body, the Maritime & Coastguard Agency (MCA), has said it will accept Method 2, and has begun developing an accreditation scheme for UK shippers in concert with the Freight Transport Association (FTA).MCA hazardous cargo advisor Keith Bradley said it was “essential that we make Method 2 work”, as with the right process it could be much more efficient.“Many members involved in the UK’s maritime trade are already operating to a variety of standards, such as AEO or ISO9000, and many companies have enterprise resource systems (ERPs) such as SAP that means they will know the weight of their cargo.“We have also had a very clear message from the port industry that it does not have the weighing equipment, nor does it want to invest in it. But ports have to consider what they are going to do if a box arrives at the port without a VGM,” he said.UK shippers will need to apply for accreditation to Method 2, with the MCA set to audit applications. FTA director of global and European Policy Chris Welsh said the organisation would be launching a service to help its members with applying for accreditation.However, John Foord, president designate of the Federation of National Associations of Ship Brokers and Agents, questioned the viability of this approach, given the increasingly tight timeframe.“It will be interesting to know if the 14,000 FTA members will all be accredited by 1 July 2016… I suspect that simply can’t happen, which means lots of UK exporters will have to use weighbridges.  But there isn’t a weighbridge near Felixstowe, for example, and there could be a significant deviations on road journeys to go via a weighbridge on the way to a port.“There really could be a lot of deviation,” Mr Foord added, “and some of the shipping lines charge shippers £2 per mile. I can see shipper easily having to an extra £50-60 per container just because of this issue.”Other regimes appear reluctant to establish accreditation schemes altogether. The World Shipping Council told The Loadstar that the US Coast Guard will not offer an accreditation scheme for shippers who wish to use Method 2.WSC vice president Anne Marie Kappel said: “That does not mean US shippers cannot utilize the method 2 option so long as they comply with the requirements in Solas to use calibrated and certified weighing equipment. US shippers can use Method 1 or Method 2.”last_img read more